2016
DOI: 10.1007/164_2016_83
View full text |Buy / Rent full text
|
Sign up to set email alerts
|

Abstract: Adenosine exerts a variety of physiological effects by binding to cell surface G-protein-coupled receptor subtypes, namely, A1, A2a, A2b, and A3. The central physiological role of adenosine is to preclude tissue injury and promote repair in response to stress. In the heart, adenosine acts as a cytoprotective modulator, linking cardiac function to metabolic demand predominantly via activation of adenosine A1 receptors (A1Rs), which leads to inhibition of adenylate cyclase activity, modulation of protein kinase … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

0
23
0
1

Year Published

2018
2018
2019
2019

Publication Types

Select...
2

Relationship

2
0

Authors

Journals

citations
Cited by 25 publications
(24 citation statements)
references
References 87 publications
(109 reference statements)
0
23
0
1
Order By: Relevance
“…Neladenoson bialanate (BAY 1067197, which is the free base of the hydrochloride BAY 86-8901) is the prodrug of the pharmacologically active compound neladenoson (BAY 84-3174), a highly potent and selective non-adenosine-like partial adenosine A1-receptor agonist suitable for once daily oral use. 7,8 The reason for the development of a partial adenosine A1-receptor agonist is that the use of full A1-receptor agonists in HF has been limited by undesirable cardiac effects such as negative inotropic, chronotropic, and dromotropic effects, including high-degree atrioventricular (AV) block, in particular with the concomitant use of -blockers. 8 In addition, a full agonist might have undesired extracardiac effects such as anti-diuretic effects (caused by vasoconstriction of the renal afferent arterioles) and neurological effects such as sedation.…”
Section: Mode Of Actionmentioning
confidence: 99%
See 2 more Smart Citations
“…Neladenoson bialanate (BAY 1067197, which is the free base of the hydrochloride BAY 86-8901) is the prodrug of the pharmacologically active compound neladenoson (BAY 84-3174), a highly potent and selective non-adenosine-like partial adenosine A1-receptor agonist suitable for once daily oral use. 7,8 The reason for the development of a partial adenosine A1-receptor agonist is that the use of full A1-receptor agonists in HF has been limited by undesirable cardiac effects such as negative inotropic, chronotropic, and dromotropic effects, including high-degree atrioventricular (AV) block, in particular with the concomitant use of -blockers. 8 In addition, a full agonist might have undesired extracardiac effects such as anti-diuretic effects (caused by vasoconstriction of the renal afferent arterioles) and neurological effects such as sedation.…”
Section: Mode Of Actionmentioning
confidence: 99%
“…Partial adenosine A1-receptor agonists can also normalize the disturbed SERCA2a protein levels in HF models, and thereby potentially improve the activity of the SERCA2a calcium pump. 7 In patients with HF, the normal, orderly transport of calcium ions in and out of the sarcoplasmic reticulum is dysregulated for several reasons, including dysfunction of SERCA2a. 9 In preclinical studies of HF, treatment with the partial adenosine A1-receptor agonist capadenoson prevented the decline in SERCA2a activity that was observed in the untreated control group.…”
Section: Mode Of Actionmentioning
confidence: 99%
See 1 more Smart Citation
“…Adenosine is ubiquitously present in the entire body and is activated in response to stress to protect against organ and tissue damage. In the heart, activation of adenosine A1 receptors modulates ischaemic injury, arrhythmogenesis, coronary and ventricular dysfunction, apoptosis, mitochondrial dysfunction, and ventricular remodelling . Heart failure (HF) with reduced ejection fraction (HFrEF) is characterized by impaired mitochondrial function and impaired calcium handling due to a decreased activity of sarcoplasmic reticulum Ca 2+ ‐ATPase (SERCA2a).…”
Section: Introductionmentioning
confidence: 99%
“…Partial agonists might limit the undesired cardiac conduction disorders and renal effects while preserving beneficial effects on the heart. Preclinical studies showed that a partial adenosine A1 receptor agonist improved cardiac function at doses that did not have undesirable effects on heart rate, AV conduction, and blood pressure . The safety and tolerability of the partial adenosine A1 receptor agonist neladenoson bialanate was studied in two small pilot studies in patients with HFrEF .…”
Section: Introductionmentioning
confidence: 99%